Project Grant R21AI193774
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Georgia Research Foundation, Inc. a Project Grant totaling $415,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 21, 2025, with completion targeted for July 31, 2027. This research initiative addresses critical gaps in understanding gram-negative bacterial resistance mechanisms by investigating the feedback signaling system that...
- Federal Project Grant Award Summary Georgia Tech Research Corp received a $775,184 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with a project completion date of July 31, 2030. This award funds investigator-initiated biomedical research to characterize small ribonucleic acids (sRNAs) in Pseudomonas aeruginosa that are highly expressed during human chronic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $247,500 to Tufts University School of Medicine on May 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research analyzing AgrA-mediated transcription regulation in Listeria monocytogenes. The project, with an ultimate completion date of April 30, 2028, will identify the complete set of genes directly regulated by AgrA, a key transcriptional...
- Federal Project Grant Award Summary The University of South Florida received a $470,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. This five-year research initiative will produce biomedical research and scientific knowledge concerning the role of SSR42, a regulatory RNA molecule, in virulence factor regulation and pathogenic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts Medical School $773,706 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research project concluding May 31, 2031. The project investigates the regulation of programmed cell death through protein succination, specifically examining how the metabolite fumarate controls pyroptosis and apoptosis...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a Project Grant of $453,750 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct biomedical research on bacterial pathogenesis and host immune response mechanisms. Awarded on February 2, 2026, with completion targeted for January 31, 2028, the project investigates how the bacterium Shigella flexneri suppresses...
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $430,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with completion scheduled for July 31, 2027. The award funds investigator-initiated biomedical research examining inter-membrane lipid signaling mechanisms in gram-negative bacteria, specifically focusing on...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Methodist Hospital Research Institute a Project Grant of $444,125 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2027. This research project will characterize a previously unknown intercellular signaling pathway in Group B Streptococcus (GBS) and determine its contribution to bacterial pathogenesis. Specifically,...
- Federal Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded Trustees of Tufts College, doing business as Tufts University School of Medicine, a Project Grant of $450,764 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was obligated on June 23, 2025, with an ultimate completion date of May 31, 2027. Research Products and Services: This grant funds research to understand the heterogeneity of necroptotic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Texas at Arlington $583,822 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research project concluding May 31, 2031. The grant funds investigation into bacterial mechanisms that evade thymineless death (TLD)—a cell death pathway triggered by anti-folate antibiotics used to treat infections including...
Augusta University Research Institute, Inc. received a $252,716 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 15, 2026, with a completion date of June 30, 2028. The grant funds biomedical research investigating the molecular mechanisms underlying lipopolysaccharide (LPS) hypersensitivity in a novel transgenic mouse model. The research examines the balance between pyroptosis (programmed inflammatory cell death) and necroptosis (lytic cell death) mediated by caspase-8 and receptor-interacting protein kinase 1 (RIPK1), with specific focus on how phosphorylation of threonine-169 in RIPK1 regulates cell death pathways in response to bacterial infection and systemic inflammatory stimuli. The grant deliverables include fundamental research findings on the pathogenic mechanisms of necroptotic cell death in acute systemic inflammatory responses, characterized mouse model phenotypes in response to Yersinia pseudotuberculosis infection and LPS challenge, and molecular validation studies examining the role of RIPK3 inhibition in rescuing LPS-induced lethality. Research outputs are expected to establish a novel mechanistic understanding of LPS-induced mortality and necroptosis induction, with potential implications for understanding septic shock and acute inflammatory disease pathology.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $252.7k | 7/15/26 |